Capricor Historical Income Statement
| CAPR Stock | USD 15.95 0.40 2.57% |
Historical analysis of Capricor Therapeutics income statement accounts such as Interest Expense of 2 M, Other Operating Expenses of 59.5 M or Total Operating Expenses of 58.2 M can show how well Capricor Therapeutics performed in making a profits. Evaluating Capricor Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Capricor Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Capricor Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Capricor Therapeutics is a good buy for the upcoming year.
Capricor |
About Capricor Income Statement Analysis
Capricor Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Capricor Therapeutics shareholders. The income statement also shows Capricor investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Capricor Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Capricor Therapeutics. It is also known as Capricor Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Capricor Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Capricor Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from Capricor Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Capricor Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Capricor Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.At this time, Capricor Therapeutics' Gross Profit is relatively stable compared to the past year. As of 02/17/2025, Total Other Income Expense Net is likely to grow to about 2.2 M, though EBIT is likely to grow to (20.6 M).
Capricor Therapeutics income statement Correlations
Click cells to compare fundamentals
Capricor Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Capricor Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 143.9K | 245.7K | 694.9K | 1.1M | 1.2M | 1.3M | |
| Other Operating Expenses | 14.0M | 21.2M | 32.2M | 49.3M | 56.6M | 59.5M | |
| Operating Income | (13.7M) | (20.9M) | (29.7M) | (24.1M) | (21.7M) | (20.6M) | |
| Ebit | (13.7M) | (20.9M) | (29.9M) | (24.1M) | (21.7M) | (20.6M) | |
| Ebitda | (13.5M) | (20.7M) | (29.2M) | (23.0M) | (20.7M) | (19.7M) | |
| Total Operating Expenses | 14.0M | 21.2M | 32.2M | 48.2M | 55.4M | 58.2M | |
| Net Income | (13.5M) | (19.4M) | (29.0M) | (22.3M) | (20.1M) | (19.1M) | |
| Income Tax Expense | (176.8K) | (613.4K) | (677.85) | (2.0) | (1.8) | (1.71) | |
| Selling General Administrative | 5.5M | 7.6M | 10.4M | 12.4M | 14.2M | 14.9M | |
| Total Revenue | 310.3K | 244.9K | 2.5M | 25.2M | 29.0M | 30.4M | |
| Gross Profit | (8.1M) | (799.0) | 1.9M | 24.1M | 27.7M | 29.1M | |
| Income Before Tax | (13.7M) | (20.0M) | (29.0M) | (22.3M) | (25.6M) | (26.9M) | |
| Total Other Income Expense Net | 32.9K | 915.9K | 677.9K | 1.8M | 2.1M | 2.2M | |
| Research Development | 8.5M | 13.6M | 21.8M | 36.4M | 41.9M | 44.0M | |
| Net Income From Continuing Ops | (13.7M) | (20.0M) | (29.0M) | (29.2M) | (26.3M) | (25.0M) | |
| Cost Of Revenue | 8.5M | 245.7K | 694.9K | 1.1M | 962.0K | 913.9K | |
| Non Operating Income Net Other | 92.1K | 32.9K | 915.9K | 677.9K | 779.5K | 1.3M | |
| Net Income Applicable To Common Shares | (7.6M) | (13.7M) | (20.0M) | (29.0M) | (26.1M) | (24.8M) | |
| Reconciled Depreciation | 143.9K | 245.7K | 533.1K | 952.9K | 1.1M | 1.2M |
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Capricor Stock
Moving against Capricor Stock
| 0.54 | SLXN | Biomotion Sciences | PairCorr |
| 0.51 | LNTH | Lantheus Holdings Earnings Call This Week | PairCorr |
| 0.49 | DRTSW | Alpha Tau Medical | PairCorr |
| 0.35 | PFE | Pfizer Inc | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.